U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Shaily Arora(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), Erik Bloomquist(Center for Drug Evaluation and Research), Tara Berman(Memorial Sloan Kettering Cancer Center), Amna Ibrahim(Beni-Suef University), Soma Ghosh(Center for Devices and Radiological Health), Reena Philip(Center for Devices and Radiological Health), Christy Osgood(Center for Drug Evaluation and Research), Shenghui Tang(United States Food and Drug Administration), Tatiana M. Prowell(United States Food and Drug Administration), Jennifer Gao(United States Food and Drug Administration), Danielle Krol(Center for Drug Evaluation and Research), Richard Pazdur(United States Food and Drug Administration), Sakar Wahby(Center for Drug Evaluation and Research), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Preeti Narayan(Center for Drug Evaluation and Research), Gwynn Ison(United States Food and Drug Administration), Suparna Wedam(United States Food and Drug Administration), Mallorie H. Fiero(Center for Drug Evaluation and Research), Melanie Royce(United States Food and Drug Administration), Mirat Shah(Center for Drug Evaluation and Research), Christina Brus(Center for Drug Evaluation and Research)
Cited by 73
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k